Terence Kelly - Cardax Independent Director
| CDXI Stock | USD 0.0002 0.00 0.00% |
Director
Dr. Terence A. Kelly, Ph.D. is Independent Director of Cardax, Inc.. Dr. Kelly has over 20 years of experience as a scientist and executive in the pharmaceutical industry starting as a medicinal chemist in 1990. Dr. Kelly is currently the President and Chief Executive Officer of CoMentis, Inc. and a founder of Kelly Pharma Research Consulting, LLC. From 1990 to 2009, Dr. Kelly served in various scientific and executive positions at Boehringer Ingelheim, where after a successful early career developing LFA1 antagonists, he led its USbased medicinal chemistry department, which included 145 scientists in the high throughput screening, computational chemistry, structural biology, combinatorial chemistry and medicinal chemistry groups. Dr. Kelly holds a B.S. degree in Chemistry at Rensselaer Polytechnic Institute and a Ph.D. degree in Chemistry at the University of Texas at Austin . He completed postdoctoral work in natural products synthesis at Yale University and holds an MBA from New York University, Stern School of Business . Dr. Kelly is the coauthor of over 25 scientific publications and serves on the College of Natural Sciences Advisory Council for the University of Texas. Dr. Kellys scientific training and his track record of delivering high quality compounds into advanced clinical studies provide valuable skills and knowledge to our Board. since 2014.
| Age | 53 |
| Tenure | 10 years |
| Phone | 808 457 1400 |
| Web | https://www.cardaxpharma.com |
Cardax Management Efficiency
The company has return on total asset (ROA) of (1.1256) % which means that it has lost $1.1256 on every $100 spent on assets. This is way below average. Cardax's management efficiency ratios could be used to measure how well Cardax manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Donald Kufe | Madrigal Pharmaceuticals | 69 | |
| Mary Gray | Sarepta Therapeutics | 65 | |
| Athena Countouriotis | Iovance Biotherapeutics | 46 | |
| Merrill McPeak | Iovance Biotherapeutics | 82 | |
| Paul Friedman | Madrigal Pharmaceuticals | 75 | |
| Robert Wilson | Madrigal Pharmaceuticals | 75 | |
| Wayne Rothbaum | Iovance Biotherapeutics | 50 | |
| Claude Nicaise | Sarepta Therapeutics | 65 | |
| William Reardon | Madrigal Pharmaceuticals | 68 | |
| Hans Wigzell | Sarepta Therapeutics | 79 | |
| Glenn Steele | PTC Therapeutics | 73 | |
| Emma Reeve | PTC Therapeutics | 57 | |
| Jerome Zeldis | PTC Therapeutics | 68 | |
| Stephanie Okey | PTC Therapeutics | 58 | |
| Scott Morenstein | Madrigal Pharmaceuticals | 38 | |
| Sanford Hillsberg | Iovance Biotherapeutics | 68 | |
| Bruce Kovner | Madrigal Pharmaceuticals | 69 | |
| James Daly | Madrigal Pharmaceuticals | N/A | |
| Richard Barry | Sarepta Therapeutics | 59 | |
| David Milligan | Madrigal Pharmaceuticals | 77 | |
| Kenneth Bate | Madrigal Pharmaceuticals | 67 | |
Management Performance
| Return On Asset | -1.13 |
Cardax Inc Leadership Team
Elected by the shareholders, the Cardax's board of directors comprises two types of representatives: Cardax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardax. The board's role is to monitor Cardax's management team and ensure that shareholders' interests are well served. Cardax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Bickerstaff, Independent Director | ||
| Nicholas Mitsakos, Executive Chairman | ||
| Frank Herringer, Director | ||
| Terence Kelly, Independent Director | ||
| David Watumull, VP of Operations, Assistant Treasurer and Assistant Secretary | ||
| Michele Galen, Independent Director | ||
| Richard Morris, Secretary | ||
| Tamar Howson, Independent Director | ||
| Gilbert Shin, Vice President - Retail Sales and Marketing | ||
| Elona Kogan, Independent Director | ||
| Makarand Jawadekar, Independent Director | ||
| John Russell, CFO, Treasurer | ||
| Jon MD, Chief Officer |
Cardax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Cardax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.13 | |||
| Operating Margin | (5.85) % | |||
| Current Valuation | 5.34 M | |||
| Shares Outstanding | 802.52 K | |||
| Price To Earning | (22.00) X | |||
| Price To Sales | 0.0008 X | |||
| Revenue | 538.95 K | |||
| Gross Profit | 342.82 K | |||
| EBITDA | (2.64 M) | |||
| Net Income | (5.06 M) |
Pair Trading with Cardax
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardax position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardax will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Cardax could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardax when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardax - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardax Inc to buy it.
The correlation of Cardax is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardax moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardax Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardax can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardax Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Cardax Pink Sheet analysis
When running Cardax's price analysis, check to measure Cardax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardax is operating at the current time. Most of Cardax's value examination focuses on studying past and present price action to predict the probability of Cardax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardax's price. Additionally, you may evaluate how the addition of Cardax to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |